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Abstract
Background: Because apolipoprotein E (apoE) and
lipopoprotein lipase (LPL) polymorphisms interact
with each other and with other factors to affect lipid
metabolism, we sought to determine their separate
and combined effects in association with ischemic
vascular disease.
Methods: We performed a case-control study of 816
subjects: 246 acute ischemic stroke patients, 234
acute myocardial infarction patients, and 336 controls.
APOE exon 4 and LPL S447X genotypes were
determined.
Results: APOE ´2 and ´4 homozygotes were
increased in stroke (4.5% vs. 1.0%, ps0.008), while in
myocardial infarction the ´4 allele was increased
(12.6% vs. 9.5%, ps0.006) but ´2 was decreased
(3.7% vs. 12.1%, ps0.000006). For subjects with either
APOE ´2 or ´4 alleles, LPL X alleles were increased in
vascular disease (ORs2.2, ps0.01). LPL X alleles dis-
played opposite tendencies toward association with
disease when subjects were divided by sex, smoking,
or APOE genotype. Meta-analysis and regression
analysis of previous studies supported the sex and
smoking dichotomies.
*Corresponding author: Larry Baum, Department of
Medicine and Therapeutics, Chinese University of Hong
Kong, Shatin, Hong Kong
Phone: q852-26323146, Fax: q852-26373852,
E-mail: lwbaum@cuhk.edu.hk
Conclusion: This is the first report of an association
of vascular disease with an interaction of APOE exon
4 and LPL S447X genotypes. Therefore, APOE geno-
types and LPL S447X interactions with apoE, sex, and
smoking may affect the risk of myocardial infarction
and ischemic stroke.
Keywords: apolipoprotein E; ischemic; lipoprotein
lipase; polymorphism; smoking.
Introduction
Polymorphisms in the lipid metabolic genes apolipo-
protein E (APOE) and lipoprotein lipase (LPL) have
been associated with ischemic cerebrovascular and
cardiovascular disease (1–14). A polymorphism in
exon 4 of APOE has three common alleles – ´2, ´3,
and ´4 – coding for E2, E3, and E4 isoforms, respec-
tively. APOE ´4 increases serum cholesterol and vas-
cular disease risk, while apoE ´2 lowers cholesterol
levels (8–12, 15). LPL helps to clear triglyceride (TG)-
rich particles from the circulation (16, 17). The LPL
S447X polymorphism, which truncates two C-termi-
nal amino acids from the LPL protein, is associated
with increased LPL protein secretion and plasma post-
heparin activity, as well as decreased plasma TG
(17–20). The X allele has been associated with
reduced risk of vascular disease (1–3, 5–7, 17).
Because apoE and LPL polymorphisms interact with
each other to affect TG and high-density lipoprotein-
cholesterol (HDL-C) levels (19, 20), as well as inter-
acting with other factors such as sex or smoking to
influence lipid levels (5, 14, 18–22), we conducted a
case-control study of these genetic and clinical factors
in acute ischemic stroke and acute myocardial infarc-
tion (MI) patients. Associations suggested by the
resulting data led us to analyze previous studies for
confirmation or refutation of these results.
Materials and methods
Subjects
Research with humans was carried out according to the prin-
ciples of the Declaration of Helsinki. The hospital’s institu-
tional Review Board approved the study, and patients or
their relatives gave informed consent. All subjects were
Hong Kong Chinese. Following admission to the acute stroke
unit of a general regional hospital, the Prince of Wales Hos-
pital, Shatin, Hong Kong, 246 consecutive acute ischemic
stroke patients were recruited from January 2002 to Novem-
ber 2003. Patients were hospitalized for cerebral infarction
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within 7 days of symptom onset. Brain computed tomogra-
phy (CT) was performed within 24 h of admission. CT evi-
dence of stroke was a requirement for inclusion in the study.
Patients with past history or CT feature of primary intracer-
ebral hemorrhage were excluded. In addition, magnetic reso-
nance imaging was performed for 90% of patients. Ultra-
sound carotid duplex, extracranial and transcranial Doppler
(TCD) ultrasound, and electrocardiography were performed
routinely for cerebral infarction patients at this hospital.
Patients were assessed by a neurologist to confirm the diag-
nosis of stroke.
From community centers for the elderly, 225 elderly peo-
ple (aged 65–74 years) were recruited, originally for a study
of the effects of exercise. Subjects with known cardiovas-
cular disease or stroke, dementia, uncontrolled/newly diag-
nosed hypertension, or impaired mobility were excluded
from the controls, as were those who were regularly per-
forming exercise. An additional 111 elderly controls (aged at
least 60 years) without known cardiovascular disease, stroke,
or dementia were recruited from outpatient clinics of the
Prince of Wales Hospital and United Christian Hospital.
Also recruited were 234 acute MI patients admitted to the
coronary care unit of the Prince of Wales Hospital between
1998 and 2002. Patients were not excluded on the basis of
age or sex. Diagnostic criteria for acute MI were as follows:
characteristic clinical presentation of precordial pain for
more than half an hour; pathological Q wave, ST elevation
or T wave inversion in the electrocardiograms, with subse-
quent evolutionary changes; and an unequivocal rise in the
aspartate aminotransferase (SGOT) level to over 45 IU/mL
on one of the three successive days, with the highest level
at least twice the lowest one in those with borderline
elevation.
Age, sex, serum lipid concentrations, and vascular risk fac-
tors, including hypertension, diabetes mellitus, and smoking
habit, were collected from controls or during acute admis-
sion for patients. Status as a current, former, or never smok-
er was determined by asking each subject for his/her
self-assessment. To measure lipids, fasting blood samples
were taken from patients the day after admission or from
controls. Hypertension was defined as systolic blood pres-
sure (SBP) )140 mm Hg or diastolic blood pressure (DBP)
)90 mm Hg on at least two occasions, or treatment with
blood pressure-lowering medication. Diabetes was defined
as fasting plasma glucose )7.0 mmol/L. Levels of TG (enzy-
matic method without glycerol blanking), total cholesterol
(TC) (enzymatic method), and HDL-C (dextran sulfate-mag-
nesium chloride precipitation) were measured on a Hitachi
analyzer (Hitachi, Tokyo, Japan), and low-density lipopro-
tein-cholesterol (LDL-C) was calculated using Friedewald’s
formula, except when TG was greater than 4.5 mmol/L. The
precision performance of these assays was within the manu-
facturer’s specifications. Blood pressure was measured in
stroke patients after they had settled in the wards. Data were
not available on passive smoking for all subjects or on SBP
and DBP for MI patients.
Cholesterol and blood pressure are typically reduced fol-
lowing MI (23, 24). In addition, many coronary artery disease
(CAD) patients took lipid-lowering statins, and some non-
hypertensive CAD patients took CAD drugs that may also
lower blood pressure (b-blockers and nitrate). Therefore, we
did not use blood pressure or lipid data gathered from MI
patients.
Analysis
LPL gene exon 9 was amplified by polymerase chain reaction
(PCR) using an annealing temperature of 558C and primers
TATTCACATCCATTTTCTTC and GTCAGCTTTAGCCCAGAA-
TG (25). MnlI restriction-enzyme digestion overnight at 378C
and separation by 12% polyacrylamide gel electrophoresis
revealed fragments of 28 and 127 bp for the 447X allele,
allowing determination of the three possible genotypes
(SS, SX, XX).
The fourth exon of APOE was amplified by a two-step nest-
ed PCR using primers as previously described (26). The six
possible APOE genotypes (´2/´2, ´2/´3, ´2/´4, ´3/´3, ´3/´4,
´4/´4) were determined by digestion with HhaI restriction
enzyme digestion overnight at 378C and separation by 12%
polyacrylamide gel electrophoresis as previously described
(27).
SPSS version 11.5 and Epi6 (World Health Organization,
Geneva, Switzerland) were used for data analysis. Differenc-
es in continuous variables were examined using Student’s
t-test or (for Table 4) ANCOVA. Because the distribution of
TG levels was skewed, log10TG was used for comparisons.
x2 Analysis was used to compare distributions of categorical
variables. p-Values were not corrected for multiple compar-
isons, and therefore readers should interpret results with
due caution until confirmed by other studies.
For multiple logistic regression, factors with the highest p-
value or which caused deviation from a good fit (i.e., p-0.05
in the Hosmer and Lemeshow test) were removed until a
value of p-0.1 was reached for the remaining factors. Fac-
tors that were then used for further adjustments shown in
Table 5 are listed in the legend to Table 5.
For meta-analysis, all published case-control studies of
ischemic heart disease or stroke were collected by searching
PubMed using the keywords lipoprotein lipase, polymor-
phism, and any of the following: stroke, cardiovascular,
infarction, and cerebrovascular. Relevant articles identified
were also examined for citations to relevant case-control
studies. Meta-analysis was performed using the random
effect model of DerSimonian and Laird, with odds ratios
weighted by the number of subjects in each group.
Results
Patient characteristics
Mean age was matched between stroke patients and
controls, although MI patients were younger (Table
1). Stroke patients were more often male, current
smokers, and had higher TG, more diabetes, and
higher blood pressure than controls. MI patients were
more often male, current smokers, or former smokers
than were controls.
Genotypes
Stroke, MI, and control groups were tested for Hardy-
Weinberg equilibrium. For each subject group, both
APOE and LPL genotypes were in equilibrium.
In stroke, examination of combinations of geno-
types suggested that APOE ´2 and ´4 homozygotes
were increased (Table 2). MI patients had a different
distribution, with more ´4 and fewer ´2 alleles.
Among subjects with hypertension, ´4 alleles were
increased in both stroke and MI: ps0.008, ORs2.2
(1.2–4.2). Both sexes exhibited similar allele associa-
tions with MI, with ´4 tending to be positively asso-
ciated with MI in men (ORs1.8, ps0.04) and women
(ORs1.9, ps0.10), and ´2 tending toward a negative
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Table 1 Characteristics of stroke, control, and MI subjects.
Stroke p Controls p MI
(ns246) (ns336) (ns234)
Age, years 70.7"12 0.24 71.0"5.9 -0.001 58.3"9.6
Men, % 54.5 0.03 45.2 -0.001 81.6
SBP, mm Hg 166"28 -0.001 142"20 –
DBP, mm Hg 85.4"19 -0.001 71.9"13 –
Hypertension, % 65.9 0.20 60.2 –
Diabetes, % 30.5 -0.001 17.5 0.99 17.4
Former smoker, %a 21.1 0.61 26.3 -0.001 43.5
Current smoker, %a 22.7 -0.001 11.3 -0.001 28.7
TC, mmol/L 5.58"1.14 0.32 5.47"0.91 –
HDL, mmol/L 1.35"0.36 0.32 1.31"0.34 –
LDL, mmol/L 3.48"1.00 0.96 3.48"0.81 –
TG, mmol/Lb 1.55 (1.44–1.67) -0.001 1.30 (1.22–1.39) –
Values are mean"SD, number of subjects, or percentage. –, no data. a p for x2 comparison with never smokers; b geometric
mean of TG (95% confidence interval).
Table 2 Distribution of APOE genotypes and alleles in stroke and MI patients and controls.
APOE Controls Stroke MI
genotype (ns311) (ns243) (ns231)
´2/´2 2 (0.6%) 7 (2.9%) 0 (0.0%)
´2/´3 60 (19.3%) 39 (16.0%) 13 (5.6%)
´2/´4 6 (1.9%) 6 (2.5%) 4 (1.7%)
´3/´3 203 (65.3%) 155 (63.8%) 164 (71.0%)
´3/´4 39 (12.5%) 32 (13.2%) 46 (19.9%)
´4/´4 1 (0.3%) 4 (1.6%) 4 (1.7%)
´2/´2q´4/´4: ps0.008, ´3/´4q´4/´4: ps0.007,
ORs4.9 (95% CI 1.3–27) ORs1.9 (95% CI 1.2–3.0)
´2/´3q´2/´2: ps0.000002,
ORs0.24 (95% CI 0.1–0.5)
Allele Controls Stroke MI
(ns622) (ns486) (ns462)
´2 70 (11.3%) 59 (12.1%) 17 (3.7%)
´3 505 (81.2%) 381 (78.4%) 387 (83.8%)
´4 47 (7.6%) 46 (9.5%) 58 (12.6%)
´4: ps0.006,
ORs1.8 (95% CI 1.2–2.7)
´2: ps0.000006,
ORs0.30 (95% CI 0.2–0.5)
association with MI in men (ORs0.3, ps0.00002) and
women (ORs0.4, ps0.11). Excluding ´2/´4 carriers,
lipid values or mean age did not differ between car-
riers of ´3/´3 and either ´2 or ´4 in either stroke or
control subjects, while in MI patients carrying ´4 com-
pared to ´3/´3, mean age was younger (55.2 vs.
59.0 years, ps0.01).
LPL genotype and allele distributions did not differ
between patients and controls (Table 3). However,
opposite associations between X alleles and disease
were observed in men vs. women, smokers vs. non-
smokers, and APOE ´3/´3 carriers vs. non-carriers
(Table 3): men, ORs0.75 (95% CI: 0.49–1.2), ps0.18;
women, ORs1.7 (1.0–3.0), ps0.04; current smokers,
ORs0.84 (0.30–2.7), ps0.72; never smoked, ORs1.3
(0.84–2.2), ps0.20; APOE ´3/´3, ORs0.81 (0.54–1.2),
ps0.30; APOE non-´3/´3, ORs2.2 (1.1–4.3), ps0.01.
To compare the effects of smoking and LPL X
alleles on vascular disease, odds ratios for disease
were calculated relative to LPL SS never smokers: Xq
never smokers, ORs1.3 (0.84–2.2), ps0.20; SS cur-
rent smokers, ORs3.5 (2.6–4.9), p-0.00001; Xq cur-
rent smokers, ORs3.0 (1.1–9.3), ps0.02. Since most
smokers were men, subjects were re-analyzed after
segregating by smoking and sex. Among never smok-
ers, the opposite odds ratios of men and women
remained nearly the same, suggesting that the sex
effect is not secondary to a smoking effect. There
were too few current smokers to obtain reliable odds
ratios after stratifying by sex and genotype. Although
MI and stroke were associated with different APOE
genotypes, both diseases tended to associate with
the combination of LPL Xq and APOE non-´3/´3
genotypes.
Several parameters differed between carriers of LPL
Xq and SS (Table 4). Among stroke patients, lipid lev-
els did not differ significantly between Xq and SS
carriers.
Logistic regression
In various subject groups, multiple logistic regression
identified different variables associated with disease.
These variables, listed in the legend to Table 5, were
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Table 3 Distribution of LPL S447X genotypes and alleles: p-values and ORs (95% CIs) on the left are for Xq genotypes, and
on the right are for X alleles.
n Genotype Allele
XX XS SS X S
Stroke patients 243 8 (3.3%) 44 (18.1%) 191 (78.6%) 60 (12.3%) 426 (87.7%)
MI patients 231 0 (0.0%) 51 (22.1%) 180 (77.9%) 51 (11.0%) 411 (89.0%)
All patients 474 8 (1.7%) 95 (20.0%) 371 (78.3%) 111 (11.7%) 837 (88.3%)
Controls 313 1 (0.3%) 64 (20.4%) 248 (79.2%) 66 (10.5%) 560 (89.5%)
ORAlls1.1 (0.7–1.5), ps0.75 ORAlls1.1 (0.8–1.6), ps0.47
Female, all patients 153 4 (2.6%) 29 (19.0%) 120 (78.4%) 37 (12.1%) 269 (87.9%)
Female, controls 176 0 (0.0%) 26 (14.8%) 150 (85.2%) 26 (7.4%) 326 (92.6%)
ORs1.6 (0.9–2.9), ps0.11 ORs1.7 (1.0–3.0), ps0.04
Male, all patients 320 4 (1.3%) 65 (20.3%) 251 (78.4%) 73 (11.4%) 567 (88.6%)
Male, controls 137 1 (0.7%) 38 (27.7%) 98 (71.5%) 40 (14.6%) 234 (75.4%)
ORs0.69 (0.43–1.1), ps0.11 ORs0.75 (0.49–1.2), ps0.18
Current smoker, all patients 117 0 (0.0%) 17 (14.5%) 100 (85.5%) 17 (7.3%) 217 (92.7%)
Current smoker, controls 35 0 (0.0%) 6 (17.1%) 29 (82.9%) 6 (8.6%) 64 (91.4%)
ORs0.82 (0.28–2.8), ps0.71 ORs0.84 (0.30–2.7), ps0.72
Ever smoker, all patients 262 2 (0.8%) 50 (19.0%) 210 (80.2%) 54 (10.3%) 470 (89.7%)
Ever smoker, controls 114 1 (0.9%) 25 (21.9%) 88 (77.2%) 27 (11.8%) 201 (88.2%)
ORs0.84 (0.48–1.5), ps0.52 ORs0.86 (0.51–1.5), ps0.53
Never smoked, all patients 196 5 (2.6%) 40 (20.4%) 151 (77.0%) 50 (12.8%) 342 (87.2%)
Never smoked, controls 198 0 (0.0%) 39 (19.7%) 159 (80.3%) 39 (9.8%) 357 (90.2%)
ORs1.2 (0.7–2.0), ps0.43 ORs1.3 (0.84–2.2), ps0.20
APOE ´3/´3, all patients 318 5 (1.6%) 58 (18.2%) 255 (80.2%) 68 (10.7%) 568 (89.3%)
APOE ´3/´3, controls 199 1 (0.5%) 49 (24.6%) 149 (74.9%) 51 (12.8%) 347 (87.2%)
ORs0.74 (0.47–1.2), ps0.15 ORs0.81 (0.54–1.2), ps0.30
APOE non-´3/´3, all patients 154 3 (1.9%) 36 (23.4%) 115 (74.7%) 42 (13.6%) 266 (86.4%)
APOE non-´3/´3, controls 104 0 (0.0%) 14 (13.5%) 90 (86.5%) 14 (6.7%) 194 (93.3%)
ORs2.2 (1.1–4.6), ps0.02 ORs2.2 (1.1–4.3), ps0.01
Table 4 Comparison of various measures in LPL Xq vs. SS carriers in subsets of subjects.
Test Subjects Measure LPL Xq p LPL SS
a MI Age, years 61.1"9.2 0.04 57.2"9.1
b Stroke NIH Stroke Scale 5.3"3.9 0.02 7.7"6.4
c Control HDL, mmol/L 1.41"0.29 0.02 1.29"0.36
d Control LDL, mmol/L 3.69"0.81 0.05 3.43"0.80
e Control TG, mmol/L 1.09 (0.96–1.22) 0.01 1.35 (1.25–1.46)
f Control: men TG, mmol/L 1.10 (0.93–1.30) 0.13 1.40 (1.21–1.63)
g Control: women TG, mmol/L 1.06 (0.88–1.28) 0.03 1.31 (1.20–1.44)
h Control: APOE ´3/´3 TG, mmol/L 1.07 (0.93–1.24) 0.05 1.32 (1.19–1.47)
i Control: APOE non-´3/´3 TG, mmol/L 1.14 (0.87–1.49) 0.10 1.40 (1.22–1.60)
Mean"SD are shown for rows (a)–(d), and geometric mean (95% confidence interval) are shown for rows (e)–(i). p-Values
were determined by ANCOVA after adjusting for the following factors: a) sex, diabetes, hypertension, and smoking, coded as
1 for never smoker, 2 for ex-smoker, and 3 for current smoker; b) age, sex, diabetes, hypertension, SBP, DBP, and smoking
coded as above; c) age, sex, diabetes, hypertension, SBP, DBP, TC, LDL, and smoking coded as above; d) age, sex, diabetes,
hypertension, SBP, DBP, HDL, log10TG, and smoking coded as above; e–i) age, sex, diabetes, hypertension, SBP, DBP, TC,
LDL, and smoking coded as above.
used to adjust the association of genotypes with dis-
ease (Table 5). The association of APOE genotypes
with MI remained highly significant after adjustment.
The odds ratio for association of APOE genotypes
with stroke was even greater than that for MI,
although this association lost its significance after
adjustment, perhaps because of the small number of
subjects with ´2/´2 or ´4/´4. The associations of LPL
Xq genotypes with vascular disease in women, never
smokers, and APOE non-´3/´3 genotypes were some-
what less significant after adjustment, although the
association among APOE non-´3/´3 genotypes
remained significant.
Interactions of genotypes with other factors were
included in the multivariate models of genotypes and
clinical characteristics for stroke and for MI. No sig-
nificant interactions were associated with MI. LPL
genotype interacted with never smoking and with
hypertension to associate with stroke.
Meta-analysis
We combined results of published case-control stud-
ies of ischemic heart disease or stroke to attempt to
confirm the tendencies we observed toward opposite
associations between LPL alleles and disease in men
vs. women and in smokers vs. non-smokers. In men,
X alleles were decreased in disease: ORs0.83 (95%
CI 0.73–0.93), ps0.002 (Figure 1). XX genotypes dis-
played a non-significant tendency toward a greater
reduction: ORs0.67 (0.41–1.09, ps0.10). However, in
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Table 5 Logistic regression analysis.
Genotype Subjects Adjusted OR (95% CI) p
for disease
a) APOE Stroke and control 3.0 (0.6–16) for stroke 0.19
b) APOE MI and control 2.4 (1.7–3.6) for MI 0.000005
c) LPL Xq Women 1.4 (0.7–2.5) for stroke or MI 0.3
d) LPL Xq Never smokers 1.1 (0.6–1.8) for stroke or MI 0.8
e) LPL Xq APOE non-´3/´3 2.2 (1.1–4.4) for stroke or MI 0.03
f) Never smoker=LPL Xq Stroke and control 3.2 (1.3–7.9) 0.02
Hypertension=LPL Xq 0.42 (0.17–1.0) 0.05
In subsets of subjects, multiple logistic regression was used to find factors associated with disease at p-0.1. These factors
were then used to adjust the associations of genotypes with diseases. The following factors were used: a) age, SBP, DBP,
diabetes, current smoking, and log10TG, for APOE ´2/´2q´4/´4; b) sex, current smoking, and former smoking, for APOE coded
as –1 for ´2/´2 or ´2/´3, 0 for ´2/´4 or ´3/´3, and 1 for ´4/´4 or ´3/´4; c) diabetes, current smoking, and former smoking; d)
sex and diabetes; e) sex and current smoking; f) age, SBP, DBP, diabetes, current smoking, and log10TG.
Figure 1 Meta-analysis of LPL. Meta-analysis of the association of LPL alleles and genotypes with vascular disease in men
(top) and women (bottom).
women, neither X alleles (ps0.52) nor XX genotypes
(ps0.63) showed a negative association with disease.
Since most studies did not present genotype results
separately by sex, we attempted to gain further infor-
mation by using regression of weighted X allele odds
ratios vs. the proportion of males for all studies,
including this report, with studies divided into inde-
pendent male and female parts when possible. The
slope of the regression was y0.16 (OR/proportion
male), ps0.15.
Since no papers presented genotype results sepa-
rately by smoking status, we used regression analysis
to compare weighted X allele odds ratios against pro-
portion of current smokers (Figure 2) (4, 28–32). The
slope of the regression was y0.88 (OR/proportion
smokers), ps0.02. Using the regression line, the pre-
dicted odds ratio was 0.4 for current smokers and 1.3
for never smokers.
Discussion
Our findings are consistent with reports of a positive
association of the APOE exon 4 ´4 allele with MI, but
only some studies reported a significant negative
association between MI and ´2 (9, 15). ApoE, as a con-
stituent of very low-density lipoprotein particles,
binds LDL receptor (LDLR), LDLR-related protein
(LRP), and other receptors, thus aiding the catabolism
of TG-rich lipoproteins and cholesterol homeostasis
(8, 9). ApoE E2, the protein isoform coded by the ´2
allele, binds LDLR poorly, which may increase the
number of LDLRs, thereby lowering cholesterol levels
(8, 10). The E4 form exhibits enhanced transfer from
HDL to TG-rich lipoproteins, accelerating hepatic rem-
nant clearance by apoE receptors and decreasing
LDLR numbers, thereby increasing cholesterol levels
(8, 10).
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Figure 2 Regression of smoking and LPL. Regression anal-
ysis for association of LPL X alleles with vascular disease by
proportion of current smokers among patients in published
studies (4, 28–32). Circle area is proportional to the number
of subjects in the study. Regression: slope y0.88, ps0.02.
The greater stroke frequency we observed not only
for ´4, but also for ´2 homozygotes has not been gen-
erally reported, perhaps because of the rarity of the
´2/´2 genotype (11). One possibility is that our obser-
vation is due to chance, since the p-value we
observed (0.008) would not meet a Bonferroni-cor-
rected significance level of 0.0016 (0.05 divided by 31,
or the number of possible ways to dichotomize the
six APOE genotypes). Meta-analysis of similar studies
might provide the additional statistical power needed
to confirm or refute this observation. If confirmed, a
possible physiological explanation could be that the
reduced receptor binding of E2 can increase circulat-
ing chylomicron remnant levels, especially after a
meal (10), which might for unknown reasons increase
the risk of stroke more than the risk of MI. Alterna-
tively, the contrasting associations of ´2 with MI and
stroke might reflect the younger age of MI than stroke
patients, rather than a difference in etiologies. In a
study comparing young and old CHD patients, ´4 was
increased in young patients, while ´2 was increased
in old patients (12).
Among subjects with hypertension, we found an
increased risk of stroke or MI associated with the ´4
allele. It may be speculated that the combination of
hypertension and ´4 has a multiplicative effect,
because these two risk factors might act through dif-
ferent pathogenic mechanisms.
The current results associated LPL Xq carriers with
several factors that suggested protection from vas-
cular disease: lower TG, delayed age of MI, and less
severe strokes. In meta-analysis, X alleles were
indeed significantly negatively associated with vas-
cular disease, although our own data showed asso-
ciations of X alleles with vascular disease only in
subsets of subjects. In a meta-analysis that expanded
on one performed 3 years ago (5), X alleles were sig-
nificantly negatively associated with stroke or cardio-
vascular disease in men, but not in women. It is pos-
sible that our result for women is an outlier that
appears to eliminate the protective effect of X alleles.
However, if the sexual divergence is confirmed in fur-
ther studies, then our failure, and that of some other
studies, to see a significant effect of X in all subjects
(combined sexes) may be due to a small sample size
or to the mix of subjects. For example, a largely male
study population may yield a significant effect, while
studies with a high proportion of women may not.
In multiple logistic regression analysis, we
observed interactive associations of LPL Xq geno-
types with stroke that may give insight into the role
of this polymorphism in vascular disease. Xq geno-
types in conjunction with hypertension appeared to
be protective, but Xq in conjunction with never smok-
ing appeared to be harmful. The effects of these two
interactions could be interpreted in a consistent way:
Xq protecting those at high risk of ischemic vascular
disease, such as smokers or those with hypertension
or other risk factors, and conversely harming those at
low risk. The apparent protective effect of Xq in men
but not women might reflect the fact that men gen-
erally have greater risk of ischemic vascular disease.
Although Xq genotypes showed decreased TG lev-
els in both female and male controls, the lack of a
protective effect against vascular disease in women
might be due to the lower TG levels in women than
men, in both genotypes (19), with reduced benefit to
women from any further TG-lowering by Xq geno-
types. An alternative explanation could be that the X
allele raises LPL activity, and that the net effect of X
on vascular risk is a balance between the resulting
reduction in circulating TG (good) and the accelerated
atherosclerosis caused by increased LPL expression
by macrophages in plaques (bad) (16). Estrogen
increases LPL expression by macrophages, thus per-
haps pushing the balance relatively more toward the
harmful end in women (33). However, estrogen also
increases HDL levels (34), which might counter this
harmful effect.
This is the first report of an association of vascular
disease with an interaction of smoking and LPL S447X
genotype. Although the type of regression analysis
that revealed this interaction may be less powerful
than meta-analysis (as shown, for example, by the
lack of significance in regression of sex vs. odds ratio
of disease with X, despite the significant effect
revealed by the corresponding meta-analysis), the
fact that regression, despite its weakness, did reveal
a significant interaction of smoking with LPL S447X
genotype suggests that this effect may be strong. In
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general, regression may be a useful tool for exami-
nation of published studies for potential association
of disease with a factor that was not stratified.
The association with vascular disease increased in
the order SS non-smoker-Xq non-smoker-Xq
smoker-SS smoker. A similar interaction order was
reported for the LPL D9N polymorphism: Nq non-
smoker-DD non-smoker-DD smoker-Nq smoker
(14). N9 and S447 reduce LPL activity and raise TG
levels (14, 17–19). Smoking decreases LPL activity
and raises TG (21), perhaps lowering risk by reducing
endothelial-located, pro-atherogenic LPL and raising
risk by reducing non-endothelial, anti-atherogenic LPL
(16). Thus, polymorphisms may affect risk via the lat-
ter effect in smokers and the former in non-smokers,
resulting in opposite effects of genotypes in smokers
vs. non-smokers. N9 LPL binds more LDL, and thus
may recruit oxidized LDL and monocytes to smoking-
induced endothelial lesions, exacerbating atheroscle-
rosis in smokers, although why N9 reduces risk
in non-smokers remains unexplained (14, 16). To
exclude the possibility that sex confounds these
smoking interactions (because most smokers are
men), subjects can be analyzed separately by smok-
ing and sex, but our study had too few current smok-
ers to do so reliably.
This is the first report of an association between
vascular disease and an interaction of APOE exon 4
and LPL S447X genotypes. The greater odds ratio
with the APOE non-´3/´3 and LPL Xq combination
did not correspond to a greater TG level in ours or a
previous study (20). It is not clear why both APOE ´2
and ´4 alleles would induce similar effects, but per-
haps the same destination is reached via different
routes. ApoE protein levels and LPL activity are higher
in ´2 carriers, and LDL-C is raised in ´4 carriers (8, 18,
20). The combination of either ´2 or ´4 with the
increased LPL activity in X carriers (17, 18, 20) might
bring more oxidized LDL and macrophages into ath-
erosclerotic plaques (16). LPL from macrophages can
be atherogenic, perhaps by binding lipoproteins to
sites of endothelial damage, converting TG-rich lipo-
proteins into remnants and creating toxic products of
lipolysis, or affecting macrophage function (16, 35).
However, apoE expression protected against athero-
sclerosis induced by macrophage-specific LPL in mice
(22), and thus the effect of APOE ´2 in our studymight
not be due to increased apoE protein levels, but rather
due to another factor, such as delayed remnant clear-
ance (15).
This study has limitations. Lack of body mass index
or lipoprotein(a) data precluded adjusting for these
factors in multivariate logistic regression. Multiple
comparisons may produce false-positive associa-
tions. Rather than reducing the chance of their occur-
rence by Bonferroni correction of significance levels,
we chose to present the data and let readers interpret
the results with appropriate caution, allowing new
associations to be uncovered that may otherwise
remain hidden. However, it will be necessary to con-
firm or refute these findings in independent popula-
tions in studies performed by other investigators.
Limitations for the MI portion of the study include lack
of some data for MI patients, and a control population
older than the MI patients. This lack of age matching
is a possible source of bias. Another limitation is that
the study design is case-control, which may be prone
to bias in subject selection and matching. On the oth-
er hand, case-control studies provide good statistical
power compared to prospective studies of similar
size. Ideally, findings of case-control studies will be
confirmed or refuted by prospective studies.
Because S447X is the most common LPL coding
polymorphism, the effects of interactions with smok-
ing or the apoE exon 4 polymorphism on population
risk would be great, and should spur authors of pre-
vious studies of this polymorphism and vascular dis-
ease to stratify their results by smoking status, sex,
and APOE genotype to confirm or refute our findings.
However, when stratified data are absent, regression
can be attempted as an alternative method of com-
bining results of multiple studies to discover
interactions.
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